Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19.

ABSTRACT:

Purpose

Convalescent plasma (CP) collected from people who recovered from COVID-19 became a rapidly available treatment modality in numerous countries, including the Czech Republic. The aims of our study were to evaluate the effectiveness and safety of CP in the treatment of COVID-19.

Methods

This retrospective observational study involved six Czech hospitals. This study enrolled patients with and without CP treatment who were hospitalized between April 2020 and April 2021. Propensity score matching and logistic regression analysis were performed to evaluate the influence of CP administration and its timing on the in-hospital survival of COVID-19 patients.

Results

A total of 1,498 patients were enrolled in the study; 406 (27%) were administered CP, and 1,092 (73%) wer

SUBMITTER: Bohonek M 

PROVIDER: S-EPMC11443855 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature